| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| L J Cohe. Risperidone. Pharmacotherapy. vol 14. issue 3. 1994-11-21. PMID:7524043. |
risperidone, a benzisoxazole derivative, is a novel antipsychotic agent that has an extremely strong binding affinity for serotonin 5-ht2 receptors, a strong binding affinity for dopamine d2 receptors, and a high affinity for alpha 1- and alpha 2-adrenergic receptors and histamine h1 receptors. |
1994-11-21 |
2023-08-12 |
Not clear |
| b' E Jahnov\\xc3\\xa. The effect of risperidone and ritanserin on human IgG and IgM synthesis in vitro. Physiological research. vol 43. issue 1. 1994-09-15. PMID:7519879.' |
risperidone decreased igg synthesis (p < 0.05) in pbmc of healthy subjects only at the highest concentration (10(-6) m) and igg synthesis enhanced by 5-ht was antagonized by risperidone. |
1994-09-15 |
2023-08-12 |
human |
| R L Gellman, G K Aghajania. Serotonin2 receptor-mediated excitation of interneurons in piriform cortex: antagonism by atypical antipsychotic drugs. Neuroscience. vol 58. issue 3. 1994-06-01. PMID:7513386. |
our data suggest that a potential site of action of the atypical antipsychotic drugs risperidone and clozapine could be antagonism of serotonin acting through serotonin2 receptors on gabaergic interneurons in cerebral cortex. |
1994-06-01 |
2023-08-12 |
rat |
| A Czyrak, G Skuza, Z Rogóz, T Frankiewicz, J Ma. Pharmacological action of zotepine and other antipsychotics on central 5-hydroxytryptamine receptor subtypes. Arzneimittel-Forschung. vol 44. issue 2. 1994-05-04. PMID:7511901. |
the effect of the atypical neuroleptic zotepine (cas 26615-21-4), in comparison with clozapine, risperidone and haloperidol, on the responsiveness of different 5-hydroxytryptamine (5-ht1) receptor subtypes to their agonists was examined in rats and mice. |
1994-05-04 |
2023-08-12 |
mouse |
| S K Min, C S Rhee, C E Kim, D Y Kan. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial. Yonsei medical journal. vol 34. issue 2. 1993-10-20. PMID:7691017. |
this study has demonstrated that the combined serotonin 5-ht2 and dopamine-d2 antagonist risperidone is an antipsychotic as potent as haloperidol. |
1993-10-20 |
2023-08-12 |
Not clear |
| O Kikumoto, Y Okamoto, H Hayakawa, N Yokota, K Kawai, N Motohashi, S Yamawak. [Effects of risperidone on catalepsy and cerebral dopamine, serotonin and GABA metabolism in the rat: comparison with haloperidol]. Yakubutsu, seishin, kodo = Japanese journal of psychopharmacology. vol 13. issue 1. 1993-07-23. PMID:7686319. |
[effects of risperidone on catalepsy and cerebral dopamine, serotonin and gaba metabolism in the rat: comparison with haloperidol]. |
1993-07-23 |
2023-08-12 |
rat |
| R Corbett, H Hartman, L L Kerman, A T Woods, J T Strupczewski, G C Helsley, P C Conway, R W Dun. Effects of atypical antipsychotic agents on social behavior in rodents. Pharmacology, biochemistry, and behavior. vol 45. issue 1. 1993-07-19. PMID:7685916. |
in vitro receptor binding studies revealed that only clozapine, risperidone, and hp 873 displayed dopamine to serotonin affinity ratios for both d2/5-hydroxytryptamine2(5-ht2)/ and d1/5-ht1a of greater than or equal to 12.9 and 1.0, respectively. |
1993-07-19 |
2023-08-12 |
rat |
| I Panocka, P Pompei, M Mass. Suppression of alcohol preference in rats induced by risperidone, a serotonin 5-HT2 and dopamine D2 receptor antagonist. Brain research bulletin. vol 31. issue 5. 1993-06-22. PMID:7684315. |
suppression of alcohol preference in rats induced by risperidone, a serotonin 5-ht2 and dopamine d2 receptor antagonist. |
1993-06-22 |
2023-08-12 |
rat |
| E M Hoenicke, S A Vanecek, J H Wood. The discriminative stimulus effects of clozapine in pigeons: involvement of 5-hydroxytryptamine1C and 5-hydroxytryptamine2 receptors. The Journal of pharmacology and experimental therapeutics. vol 263. issue 1. 1992-11-20. PMID:1403790. |
5-ht antagonists selective for 5-ht2 vs. 5-ht1c receptors (e.g., ketanserin, pirenperone, risperidone and methiothepin) failed to produce substantial clozapine-appropriate responding. |
1992-11-20 |
2023-08-11 |
Not clear |
| R L Borison, A P Pathiraja, B I Diamond, R C Meibac. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacology bulletin. vol 28. issue 2. 1992-10-01. PMID:1381102. |
risperidone represents a unique pharmacology of potent antagonism of both serotonin and dopamine receptors. |
1992-10-01 |
2023-08-11 |
Not clear |
| S L Heylen, Y G Gelder. Risperidone, a new antipsychotic with serotonin 5-HT2 and dopamine D2 antagonistic properties. Clinical neuropharmacology. vol 15 Suppl 1 Pt A. 1992-09-14. PMID:1379877. |
risperidone, a new antipsychotic with serotonin 5-ht2 and dopamine d2 antagonistic properties. |
1992-09-14 |
2023-08-11 |
Not clear |
| H J Möller, E Pelzer, W Kissling, T Riehl, T Wernick. Efficacy and tolerability of a new antipsychotic compound (risperidone): results of a pilot study. Pharmacopsychiatry. vol 24. issue 6. 1992-06-10. PMID:1725925. |
risperidone is a new benzisoxazole derivative displaying a very potent serotonin antagonism and a potent dopamine antagonism in pharmacological studies. |
1992-06-10 |
2023-08-11 |
Not clear |
| J E Leysen, P M Janssen, W Gommeren, J Wynants, P J Pauwels, P A Jansse. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Molecular pharmacology. vol 41. issue 3. 1992-04-16. PMID:1372084. |
the in vitro receptor binding and monoamine uptake inhibition profiles, comprising 29 receptors and four monoamine uptake systems, revealed that ocaperidone and risperidone bound primarily, and with the highest affinity thus far reported, to serotonin 5ht2 receptors (ki values of 0.14 and 0.12 nm, respectively). |
1992-04-16 |
2023-08-11 |
human |
| A A Megens, F H Awouters, T F Meert, K H Schellekens, C J Niemegeers, P A Jansse. Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598). The Journal of pharmacology and experimental therapeutics. vol 260. issue 1. 1992-02-18. PMID:1370538. |
ocaperidone also antagonized serotonin agonist (tryptamine, mescaline or 5-hydroxytryptophan)-induced behavioral effects (0.011-0.064 mg/kg) and was, thereby, equipotent with risperidone (0.014-0.056 mg/kg) and at least as potent as ritanserin (0.037-0.13 mg/kg). |
1992-02-18 |
2023-08-11 |
Not clear |
| A A Megens, F H Awouters, T F Meert, K H Schellekens, C J Niemegeers, P A Jansse. Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598). The Journal of pharmacology and experimental therapeutics. vol 260. issue 1. 1992-02-18. PMID:1370538. |
ocaperidone displayed its serotonin and dopamine antagonism at the same dose levels, in contrast to risperidone, which was a predominant serotonin antagonist. |
1992-02-18 |
2023-08-11 |
Not clear |
| J Gerlac. New antipsychotics: classification, efficacy, and adverse effects. Schizophrenia bulletin. vol 17. issue 2. 1991-10-03. PMID:1715608. |
(4) antipsychotics such as clozapine and risperidone, which affect d2/d3 receptors as well as 5ht, alpha 1, and/or d1 receptors appear to have the most pronounced antipsychotic effect. |
1991-10-03 |
2023-08-11 |
Not clear |
| A Schotte, K de Bruyckere, P F Janssen, J E Leyse. Receptor occupancy by ritanserin and risperidone measured using ex vivo autoradiography. Brain research. vol 500. issue 1-2. 1990-02-20. PMID:2481562. |
in this study, autoradiographical techniques are introduced to investigate the occupancy of serotonin 5-ht2, dopamine d2 and alpha 1-adrenergic receptors after the in vivo administration of ritanserin, a selective, potent and long-acting 5-ht2 antagonist and of risperidone, a very potent 5-ht2 antagonist and potent d2 and alpha 1 antagonist. |
1990-02-20 |
2023-08-11 |
rat |